Original site: www.cdc.gov/mmwr/preview/mmwrhtml/00000847.htm RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
Epidemiologic Notes and Reports Antibody Response to A/Taiwan/
86 (H1N1) Virus in Young Adults Receiving Supplemental Monovalent
A/
Taiwan/86 Influenza Vaccine Following Trivalent
Influenza Vaccine
In accordance with recent recommendations (1), monovalent
A/Taiwan/86 (H1N1) influenza vaccine was given to U.S. Air Force
recruits who had been vaccinated 2 to 3 months previously with the
1986/87 trivalent influenza vaccine. Thirty-four recruits
volunteered
sera for antibody studies of immune response. At the time the
A/Taiwan/86 vaccine was administered, 100% of the recruits had
serum
hemagglutination-inhibition (HI) antibody titers of greater than
or
equal to 32 to the A/Chile/83 (H1N1) virus included in the
trivalent
vaccine, but only 45% had such titers to the A/Taiwan/86 strain.
Following immunization with the supplemental monovalent vaccine,
the
proportion of recruits with HI antibody titers of greater than or
equal to 32 against A/Taiwan/86 virus increased to 100%, and 92%
had
HI titers greater than or equal to 128 (Table 1).
Reported by G Meiklejohn, MD, Patricia Graves, School of Medicine,
Univ of Colorado Health Sciences Center, Denver, Col G Hutchison,
Lowry Air Force Base, Colorado; Lt Col M Evans, MD, Lackland Air
Force
Base, Texas; Influenza Br, Div of Viral Diseases, Center for
Infectious Diseases, CDC.
Editorial Note
Editorial Note: The above findings are consistent with previous
reports (2,3) that the A/Chile/83 component of the 1986/87
trivalent
vaccine may provide inadequate protection against the A/Taiwan/86
virus; protection may be boosted by use of the monovalent
A/Taiwan/86
vaccine as recommended (1). Because all recently reported
outbreaks
of influenza A/Taiwan/86-like virus, where laboratory confirmation
has
been obtained, have occurred in children or young adults, it is
particularly important that high-risk individuals in these age
groups
be given priority for vaccination with the supplemental A/Taiwan/86
vaccine. (See "Update of Influenza Activity, Availability of
Influenza Vaccines, and Recommendations and Precautions for the Use
of
Amantadine", pp. 805-807.)
CDC. Antigenic variation of recent influenza A(H1N1) viruses.
MMWR
1986;35:510-2.
CDC. Influenza activity in civilian and military populations
and
key points for use of influenza vaccines. MMWR 1986;35:729-31.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
